A Woolfrey

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Int J Hematol 76:184-9. 2002
  2. ncbi request reprint Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome
    A E Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington Departments of Pediatrics and Medicine, Seattle, WA, USA
    Blood 92:3546-56. 1998
  3. pmc HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category
    Ann Woolfrey
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1382-7. 2010
  4. pmc Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation
    Ann E Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3484-7. 2008
  5. pmc HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation
    Ann Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:885-92. 2011
  6. ncbi request reprint Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children
    Ann E Woolfrey
    Pediatric Transplantation, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 99:2002-8. 2002
  7. ncbi request reprint Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency
    A Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109, USA
    Curr Opin Pediatr 13:539-45. 2001
  8. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
    L Feinstein
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, P O Box 19024, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 938:328-37; discussion 337-9. 2001
  9. ncbi request reprint Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation
    E W Petersdorf
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 345:1794-800. 2001
  10. ncbi request reprint Non-myeloablative hematopoietic stem cell transplantation
    M Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Transfus Clin Biol 8:231-4. 2001

Detail Information

Publications32

  1. ncbi request reprint Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Int J Hematol 76:184-9. 2002
    ..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options...
  2. ncbi request reprint Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome
    A E Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington Departments of Pediatrics and Medicine, Seattle, WA, USA
    Blood 92:3546-56. 1998
    ..In addition, allogeneic BMT provides effective therapy for the majority of infants with MDS...
  3. pmc HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category
    Ann Woolfrey
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1382-7. 2010
    ..However, for patients with intermediate-risk disease, transplantation with peripheral blood from a 10/10 MUD is associated with lower survival than an MSD...
  4. pmc Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation
    Ann E Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3484-7. 2008
    ..We conclude that allogeneic HCT offers the unique ability to characterize de novo HIV-1-specific immune responses. This clinical trial was registered at ClinicalTrials.gov (identifier: NCT00112593)...
  5. pmc HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation
    Ann Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:885-92. 2011
    ..HLA-C antigen-mismatched unrelated PBSC donors were associated with worse outcomes compared with 8/8 HLA-matched donors. The study's limited power due to small sample size precludes conclusions about other mismatches...
  6. ncbi request reprint Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children
    Ann E Woolfrey
    Pediatric Transplantation, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 99:2002-8. 2002
    ..Outcome was particularly favorable in younger patients with early phases of the disease...
  7. ncbi request reprint Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency
    A Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109, USA
    Curr Opin Pediatr 13:539-45. 2001
    ..Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treating life-threatening immune deficiencies...
  8. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
    L Feinstein
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, P O Box 19024, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 938:328-37; discussion 337-9. 2001
    ..Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting...
  9. ncbi request reprint Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation
    E W Petersdorf
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 345:1794-800. 2001
    ..that allele mismatches that are detectable only at the DNA level are less immunogenic than those that are serologically detectable and thereby are associated with a lower risk of graft failure after hematopoietic-cell transplantation..
  10. ncbi request reprint Non-myeloablative hematopoietic stem cell transplantation
    M Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Transfus Clin Biol 8:231-4. 2001
    ....
  11. ncbi request reprint Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 872:372-5; discussion 375-6. 1999
    ..This paper describes the development of nonmyeloablative marrow transplant programs that have little toxicity in a canine model and their translation to patients with malignant and nonmalignant hematological diseases...
  12. ncbi request reprint Genomics of unrelated-donor hematopoietic cell transplantation
    E Petersdorf
    University of Washington, School of Medicine, 1959 NE Pacific Street, Seattle, Washington 98105, USA
    Curr Opin Immunol 13:582-9. 2001
    ..Delineation of the function of these markers as transplantation determinants may provide alternative means for optimizing the results of hematopoietic cell transplantation...
  13. ncbi request reprint Trends in transplantation of hematopoietic stem cells from unrelated donors
    C Anasetti
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Curr Opin Hematol 8:337-41. 2001
    ..Improved methods for transplantation may provide the opportunity to further decrease treatment-related toxicity and improve survival...
  14. pmc Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation
    M S Thakar
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 19024, USA
    Bone Marrow Transplant 46:539-44. 2011
    ..Three patients are alive and well at a median of 45.9 (range, 20.9-68.1) months after transplant. In summary, this FLU-based regimen facilitates stable engraftment of unrelated PBSCs, but is associated with significant chronic GVHD...
  15. ncbi request reprint HLA matching in hematopoietic cell transplantation
    E M Mickelson
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Hum Immunol 61:92-100. 2000
    ..The use of these methods to optimize donor selection will improve both donor identification and the success of unrelated donor transplants...
  16. ncbi request reprint The biological significance of HLA-DP gene variation in haematopoietic cell transplantation
    E W Petersdorf
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D4 100, Seattle, WA 98109 1024, USA
    Br J Haematol 112:988-94. 2001
    ..1; P = 0.01). HLA-DP plays an important role in the alloimmune response. A threshold effect of multiple HLA-DP disparities is evident in determining the risk of acute GVHD after haematopoietic cell transplantation from unrelated donors...
  17. ncbi request reprint Improving availability and safety of unrelated donor transplants
    C Anasetti
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle 98109, USA
    Curr Opin Oncol 12:121-6. 2000
    ..The availability of more selective immunosuppressive agents provides the opportunity to decrease treatment-related toxicity and graft-versus-host disease...
  18. ncbi request reprint Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome
    Wolfgang A Bethge
    Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington 98109 1024, USA
    Exp Hematol 31:974-80. 2003
    ..This study analyzes the effect of interventions aimed at reinducing remissions in patients with relapse or progression of malignant disease following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative conditioning...
  19. pmc Thyroid function following hematopoietic cell transplantation in children: 30 years' experience
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:306-8. 2009
    ..008). Thyroid tumors occurred at a median of 9.9 (4.5-22.3) years after HCT and included 13 with papillary carcinoma and 5 with benign adenomas. Children who receive a HCT should be monitored for thyroid abnormalities throughout life...
  20. pmc Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodies
    Jonathan A Gutman
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Transplantation 87:415-8. 2009
    ..Virtual crossmatch can be used to screen for donor-directed antibodies in CBT. As possible, units should be changed to avoid sensitized mismatches...
  21. pmc Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis
    Jonathan A Gutman
    Fred Hutchinson Cancer Research Center, Seattle, Washington Medicine and Pediatrics, University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 15:1122-9. 2009
    ..These data support increased investigation of the use of CBT...
  22. pmc Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
    LAURI M BURROUGHS
    Fred Hutchinson Cancer Research Center, Seattle, Wash 98109 1024, USA
    J Allergy Clin Immunol 126:1000-5. 2010
    ..Hematopoietic cell transplantation is currently the only viable option for long-term survival, but patients are frequently very ill and may not tolerate traditional myeloablative conditioning regimens...
  23. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  24. ncbi request reprint Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson CRC, Seattle, Washington, USA
    Biol Blood Marrow Transplant 13:683-90. 2007
    ..12 (-2.28 to +4.24) among the controls and +1.43 (-0.29 to +3.72) for the bisphosphonate group (P = .0002). The greatest improvement in BMD was observed in children who received therapy with bisphosphonates...
  25. ncbi request reprint Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 23:1993-2003. 2005
    ..This approach relied on graft-versus-tumor (GVT) effects for control of malignancy...
  26. pmc Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia
    Jean E Sanders
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 105:3749-56. 2005
    ..Late effects included growth and other hormone deficiencies. These data demonstrate that infants with ALL and MLL gene have excellent DFS when they received transplants in CR1, and consideration for transplantation in CR1 is warranted...
  27. ncbi request reprint Final adult height of patients who received hematopoietic cell transplantation in childhood
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, D5 280, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 105:1348-54. 2005
    ..02) also showed more rapid growth than their counterparts. These data demonstrate that GH therapy improves the final height of young children after fractionated TBI...
  28. ncbi request reprint Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia
    Soheil Meshinchi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:706-13. 2003
    ..Because a higher tumor burden at the time of second HSCT was associated with a higher risk of subsequent relapse, patients might benefit from reinduction therapy before the second HSCT...
  29. ncbi request reprint Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century
    M Maris
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109-1024, USA
    Front Biosci 6:G13-6. 2001
    ....
  30. ncbi request reprint Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children
    Ann E Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, USA
    Int J Hematol 76:271-7. 2002
    ..Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treatment of life-threatening immune deficiencies...
  31. ncbi request reprint Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
    William J Hogan
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 103:78-84. 2004
    ..Aggressive malignancies (mainly advanced disease) and later development of jaundice after transplantation predicted inferior survival...
  32. pmc Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    University of Liege, Liege, Belgium
    Biol Blood Marrow Transplant 13:1041-8. 2007
    ..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning...